Profile data is unavailable for this security.
About the company
Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. It is also building a Cell therapy portfolio.
- Revenue in AUD (TTM)3.97m
- Net income in AUD-10.43m
- Incorporated2020
- Employees--
- LocationChimeric Therapeutics LtdLevel 3, 62 Lygon Street, CarltonMELBOURNE 3053AustraliaAUS
- Phone+61 39824-5254
- Fax+61 39822-7735
- Websitehttps://chimerictherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPH Global Ltd | 352.38k | -1.49m | 4.71m | 31.00 | -- | -- | -- | 13.36 | -0.0026 | -0.0026 | 0.0006 | -0.0014 | 0.8548 | 3.49 | 2.27 | -- | -360.76 | -76.32 | -- | -214.32 | 6.86 | 17.08 | -422.04 | -156.56 | 0.1995 | -43.14 | -- | -- | 220.43 | -13.56 | 24.87 | -- | -- | -- |
| Invion Ltd | 0.00 | -8.81m | 6.77m | 8.00 | -- | 0.8127 | -- | -- | -0.1183 | -0.1183 | 0.00 | 0.0972 | 0.00 | -- | -- | -- | -70.63 | -29.16 | -77.64 | -30.88 | -- | -- | -- | -147.34 | -- | -- | 0.00 | -- | -100.00 | -- | -56.50 | -- | -- | -- |
| Vectus Biosystems Ltd | 18.77k | -1.78m | 6.95m | -- | -- | -- | -- | 370.08 | -0.0334 | -0.0334 | 0.0004 | -0.0048 | 0.0134 | -- | 0.0266 | -- | -126.57 | -79.19 | -247.24 | -189.44 | -- | -- | -9,468.62 | -10,165.01 | 0.9301 | -554.06 | -- | -- | -75.58 | 73.61 | 23.99 | -- | -- | -- |
| Nexalis Therapeutics Ltd | 837.55k | -1.33m | 7.09m | -- | -- | -- | -- | 8.46 | -0.006 | -0.006 | 0.0037 | -0.0041 | 0.8301 | -- | 2.50 | -- | -131.43 | -73.85 | -- | -100.32 | -- | -- | -158.33 | -369.19 | -- | -- | -- | -- | -66.38 | 21.67 | 16.21 | -- | -- | -- |
| Percheron Therapeutics Ltd | 371.10k | -14.92m | 7.61m | 8.00 | -- | 0.7609 | -- | 20.51 | -0.0149 | -0.0149 | 0.0004 | 0.0092 | 0.0275 | -- | 0.2824 | -- | -110.67 | -79.28 | -153.98 | -96.61 | -- | -- | -4,021.00 | -3,694.96 | -- | -1,093.50 | 0.0026 | -- | -39.71 | 64.80 | -25.19 | -- | -6.74 | -- |
| Biotron Ltd | 0.00 | -318.57k | 8.11m | 4.00 | -- | 7.21 | -- | -- | -0.0004 | -0.0004 | 0.00 | 0.0004 | 0.00 | -- | -- | -- | -43.23 | -86.63 | -206.95 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 90.73 | -- | -- | -- |
| Chimeric Therapeutics Ltd | 3.97m | -10.43m | 8.84m | -- | -- | 2.14 | -- | 2.23 | -0.007 | -0.007 | 0.0028 | 0.0009 | 0.2154 | -- | 1.73 | -- | -56.62 | -66.67 | -171.92 | -112.02 | 78.66 | -- | -262.83 | -2,013.07 | -- | -62.30 | 0.7162 | -- | -- | -- | 16.76 | -- | -- | -- |
| Invex Therapeutics Ltd | 473.31k | -835.91k | 9.39m | -- | -- | 2.07 | -- | 19.85 | -0.0111 | -0.0111 | 0.0063 | 0.0605 | 0.0894 | -- | 5.09 | -- | -15.79 | -15.04 | -16.83 | -15.74 | -- | -- | -176.61 | -419.12 | -- | -- | 0.00 | -- | -72.92 | 22.74 | 70.95 | -- | -- | -- |
| Adalta Ltd | 626.72k | -4.36m | 10.20m | -- | -- | -- | -- | 16.27 | -0.0039 | -0.0039 | 0.0005 | -0.0001 | 0.2993 | -- | 1.70 | -- | -208.36 | -70.41 | -611.82 | -126.24 | -- | -- | -696.16 | -207.18 | -- | -15.14 | -- | -- | -61.02 | -28.97 | 16.33 | -- | -- | -- |
| Imagion Biosystems Ltd | 1.06m | -2.20m | 10.79m | -- | -- | -- | -- | 10.22 | -0.0177 | -0.0177 | 0.0082 | -0.0192 | 1.45 | -- | 1,173.13 | -- | -302.58 | -76.63 | -- | -102.36 | -- | -- | -208.52 | -911.24 | -- | -0.7972 | -- | -- | -18.54 | 22.02 | 83.43 | -- | -- | -- |
| BPH Energy Ltd | 914.02k | -1.21m | 10.83m | 2.00k | -- | 0.2569 | -- | 11.85 | -0.001 | -0.001 | 0.0008 | 0.0311 | 0.0235 | -- | 8.56 | -- | -3.10 | 9.05 | -3.15 | 9.45 | -- | -- | -132.17 | 431.04 | -- | -0.8233 | 0.0022 | -- | -0.8344 | 28.34 | 48.93 | 43.33 | -- | -- |
| Cambium Bio Ltd | 719.38k | -3.57m | 11.25m | -- | -- | 4.35 | -- | 15.64 | -0.2766 | -0.2766 | 0.0455 | 0.1126 | 0.2011 | -- | 4.09 | -- | -99.90 | -41.30 | -150.85 | -75.44 | 70.61 | -- | -496.86 | -118.71 | -- | -- | 0.1378 | -- | 419.43 | -16.63 | -70.42 | -- | -- | -- |
